What should I do if I develop drug resistance after taking eltrombopag/eltrombopag?

Eltrombopag/Eltrombopag is an oral drug that belongs to the thrombopoietin receptor agonists (TPO-RAs). It works by simulating thrombopoietin in the body and inhibiting stem cells in the bone marrow from producing more platelets, thereby increasing the number of platelets. Commonly used to treat thrombocytopenia.

When a patient develops drug resistance after taking eltrombopag, it means that the drug no longer works as expected. Patients may experience accelerated drug metabolism and clearance, resulting in decreased drug concentration in the body. Changes in drug targets: Patients may have mutations in the target of eltrombopag, making it unable to bind to the drug. Resistance through other mechanisms: Patients may have resistance through other mechanisms, such as changes in cell signaling pathways that reduce the effectiveness of the drug.

When patients develop resistance to eltrombopag, they should promptly consult a professional doctor or pharmacist. They can provide solutions on a case-by-case basis, and the doctor may adjust the patient's dose of eltrombopag or give a stronger drug. Depending on the patient's symptoms and platelet count, the doctor may prescribe other treatments, such as blood transfusions, immune globulin, etc., to increase platelet levels. If eltrombopag no longer works for a patient, the doctor may recommend trying other medications or interventional treatments.

The specific treatment plan should be determined by the doctor based on the patient's condition. It is very important to communicate with the doctor in time and develop a suitable personalized treatment plan. Also, it is key to follow your doctor's advice and use your medication correctly according to the directions for use.